Arrowhead Pharmaceuticals (ARWR) Operating Leases (2019 - 2025)
Arrowhead Pharmaceuticals (ARWR) has disclosed Operating Leases for 7 consecutive years, with $102.1 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Operating Leases fell 11.85% year-over-year to $102.1 million, compared with a TTM value of $102.1 million through Dec 2025, down 11.85%, and an annual FY2025 reading of $104.1 million, down 6.23% over the prior year.
- Operating Leases was $102.1 million for Q4 2025 at Arrowhead Pharmaceuticals, down from $104.1 million in the prior quarter.
- Across five years, Operating Leases topped out at $118.9 million in Q1 2024 and bottomed at $22.5 million in Q4 2021.
- Average Operating Leases over 5 years is $78.6 million, with a median of $91.0 million recorded in 2023.
- The sharpest move saw Operating Leases skyrocketed 253.37% in 2022, then fell 11.85% in 2025.
- Year by year, Operating Leases stood at $22.5 million in 2021, then surged by 253.37% to $79.5 million in 2022, then skyrocketed by 44.91% to $115.2 million in 2023, then rose by 0.61% to $115.9 million in 2024, then dropped by 11.85% to $102.1 million in 2025.
- Business Quant data shows Operating Leases for ARWR at $102.1 million in Q4 2025, $104.1 million in Q3 2025, and $105.7 million in Q2 2025.